Kezar Life Sciences (NASDAQ:KZR) Stock Rating Reaffirmed by HC Wainwright

Kezar Life Sciences (NASDAQ:KZRGet Free Report)‘s stock had its “neutral” rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Wednesday, Marketbeat.com reports.

Kezar Life Sciences Price Performance

NASDAQ:KZR opened at $0.83 on Wednesday. The firm has a market cap of $60.10 million, a PE ratio of -0.59 and a beta of 0.20. The company’s 50-day moving average price is $0.61 and its two-hundred day moving average price is $0.70. The company has a quick ratio of 9.58, a current ratio of 9.58 and a debt-to-equity ratio of 0.05. Kezar Life Sciences has a 12 month low of $0.52 and a 12 month high of $1.14.

Kezar Life Sciences (NASDAQ:KZRGet Free Report) last announced its earnings results on Tuesday, August 13th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.04. On average, equities analysts anticipate that Kezar Life Sciences will post -1.2 EPS for the current fiscal year.

Institutional Trading of Kezar Life Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. Affinity Asset Advisors LLC acquired a new stake in shares of Kezar Life Sciences in the first quarter valued at approximately $1,588,000. Stonepine Capital Management LLC bought a new stake in shares of Kezar Life Sciences during the second quarter worth $630,000. Acadian Asset Management LLC lifted its stake in shares of Kezar Life Sciences by 42.5% during the first quarter. Acadian Asset Management LLC now owns 1,790,838 shares of the company’s stock valued at $1,613,000 after acquiring an additional 534,203 shares during the period. Acuitas Investments LLC boosted its holdings in Kezar Life Sciences by 42.8% in the second quarter. Acuitas Investments LLC now owns 986,785 shares of the company’s stock valued at $592,000 after acquiring an additional 295,956 shares during the last quarter. Finally, Marquette Asset Management LLC bought a new position in Kezar Life Sciences in the first quarter valued at about $114,000. 67.90% of the stock is currently owned by institutional investors and hedge funds.

Kezar Life Sciences Company Profile

(Get Free Report)

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.

Featured Stories

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.